Call for Abstract

International Conference on Hepatitis, will be organized around the theme “En Route to Hepatitis Free Future”

HEPATITIS MEET 2021 is comprised of keynote and speakers sessions on latest cutting edge research designed to offer comprehensive global discussions that address current issues in HEPATITIS MEET 2021

Submit your abstract to any of the mentioned tracks.

Register now for the conference by choosing an appropriate package suitable to you.

  • Track 1-1Hepatitis A
  • Track 1-2Auto immune hepatitis
  • Track 1-3Non- alcoholic steatohepatitis
  • Track 1-4Hepatitis D
  • Track 1-5Viral hepatitis
  • Track 1-6Hepatitis E
  • Track 2-1Clotting disorders
  • Track 2-2Chronic liver diseases
  • Track 2-3Iatrogenic contamination
  • Track 2-4Alcoholic hepatitis
  • Track 2-5Non-alcoholic steatohepatitis
  • Track 3-1Internal ribosome entry site
  • Track 3-2Capsid
  • Track 3-3Hepatogenous
  • Track 3-4Minichromosomes
  • Track 3-5Liver cirrhosis
  • Track 4-1Natural killer cells
  • Track 4-2Adaptive immunity
  • Track 4-3Apoptosis
  • Track 4-4Hepatic cirrhosis
  • Track 4-5Inflammation
  • Track 5-1Aspartame transaminase
  • Track 5-2Liver biopsy
  • Track 5-3Magnetic resonance imaging
  • Track 5-4Partial thromboplastin time
  • Track 5-5Serum albumin
  • Track 6-1Immunization
  • Track 6-2Hepatocellular carcinoma
  • Track 6-3Hepatitis B vaccine
  • Track 6-4Food and Drug Administration
  • Track 6-5Dialysis
  • Track 6-6Non-alcoholic steatohepatitis
  • Track 7-1Intravenous administration
  • Track 7-2Lamivudine
  • Track 7-3Tenofovir
  • Track 7-4Telbivudine
  • Track 7-5Pegylated interferon
  • Track 8-1Dyslipidemia
  • Track 8-2Cardiac failure
  • Track 8-3Person with advanced hepatic cancer
  • Track 8-4HIV infected patient
  • Track 8-5Alcohol abuse
  • Track 9-1Neominophagen
  • Track 9-2Danshen
  • Track 9-3Phyllanthus
  • Track 9-4Silymarin
  • Track 9-5Glycyrrhizin
  • Track 10-1Hepatoblastoma
  • Track 10-2Intrahepatic cholangiocarcinoma
  • Track 10-3Angiosarcoma
  • Track 10-4Hemangiosarcoma
  • Track 11-1Abnormalities in circulation
  • Track 11-2Hepatic dysfunction
  • Track 11-3Jaundice
  • Track 11-4Altered mental status
  • Track 11-5Oliguria
  • Track 11-6Ascites
  • Track 12-1Anorexia
  • Track 12-2Fatigue
  • Track 12-3Accumulation of bilirubin leading to jaundice
  • Track 12-4Weakness
  • Track 12-5Nausea
  • Track 12-6Weight loss
  • Track 12-7Bleeding or bruising
  • Track 13-1Irritable bowel syndrome
  • Track 13-2Liver
  • Track 13-3Gall bladder
  • Track 13-4Pancreatitis
  • Track 13-5Celiac disease
  • Track 13-6Alimentary canal
  • Track 14-1Pancreatic cancer
  • Track 14-2Diabetes mellitus
  • Track 14-3Pancreas malfunction
  • Track 14-4Cystic fibrosis
  • Track 14-5Intraductal Papillary Mucinous Neoplasm (IPMN)
  • Track 14-6Exocrine pancreatic insufficiency
  • Track 14-7Hemosuccus pancreaticus
  • Track 14-8Pseudocysts
  • Track 15-1COVID-19
  • Track 15-2Liver enzymes
  • Track 15-3Liver enzymes
  • Track 15-4Acute respiratory distress
  • Track 15-5SARS-CoV-2
  • Track 15-6Innate immune response
  • Track 16-1Sofosbuvir
  • Track 16-2Ledipasvir
  • Track 16-3Simeprevir
  • Track 16-4Daclatasvir
  • Track 16-5Paritaprevir/Ritonavir/Ombitasvir plus Dasabuvir
  • Track 16-6Elbasvir/Grazoprevir